Yazar "Besisik, Sevgi Kalayoglu" seçeneğine göre listele

Listeleniyor 1 - 5 / 5
  • Küçük Resim Yok
    Öğe
    Early Access Program Results From Turkey and a Literature Review on Daratumumab Monotherapy Among Heavily Pretreated Patients With Relapsed/Refractory Myeloma
    (Cig Media Group, Lp, 2020) Beksac, Meral; Aydin, Yildiz; Goker, Hakan; Turgut, Mehmet; Besisik, Sevgi Kalayoglu; Cagirgan, Seckin; Tekgunduz, Emre
    The present study investigated the efficacy and safety profile of daratumumab monotherapy in 42 patients with relapsed refractory multiple myeloma through a Turkish early access program. the current findings have confirmed the efficacy of daratumumab monotherapy in heavily pretreated patients with refractory multiple myeloma because of the deep and durable responses and favorable safety and tolerability profile. Background: in countries where frontline drug approval is limited to first-generation proteasome inhibitors or immunomodulatory drugs, relapses have been both more frequent and less durable. We investigated real world data on the efficacy and safety of daratumumab monotherapy among patients with relapsed refractory multiple myeloma (RRMM) from Turkey using a prospective early access program. Patients and Methods: A total of 42 patients with RRMM after a minimum of 3 previous lines of proteasome inhibitor/immunomodulatory drug-based treatments were included from 25 centers across Turkey. Daratumumab monotherapy was administered intravenously at a dose of 16 mg/kg weekly (cycles 1-2), on alternate weeks (cycles 3-6), and monthly thereafter. Results: the median daratumumab monotherapy duration was 5.5 months (range, 0.2-28.7 months). the overall response rate was 45.2%, including 14 (33.3%) partial responses, 4 (9.5%) very good partial responses, and 1 (2.4%) complete response. the median duration of response was 4.9 months. the median progression-free survival (PFS) was 5.5 (95% confidence interval, 2.6-8.4 months) with 12- and 18-month PFS rates of 35.7% and 31.0%, respectively. the median overall survival was not reached; the 12- and 18-month overall survival rates were 64.3% and 59.5%, respectively. the depth of response had a significant effect on PFS (log-rank test, P = .026). Overall, of the 76 adverse events reported, 33 (43.4%) were grade >= 3; only 4 (9.52%) were grade 3 infusion-related reactions. No infusion-related reactions or adverse events led to treatment discontinuation. Conclusion: the present findings from our daratumumab early access program have confirmed the efficacy and safety profile of daratumumab monotherapy in heavily pretreated Turkish patients with RRMM.
  • Küçük Resim Yok
    Öğe
    Incidence and risk factors for hepatic sinusoidal obstruction syndrome after allogeneic transplantation: Retrospective multicenter study of Turkish hematology research and education group (THREG), updated data
    (Nature Publishing Group, 2019) Soyer, Nur; Gunduz, Mehmet; Tekgunduz, Emre; Deveci, Burak; Ozdogu, Hakan; Sahin, Handan Haydaroglu; Turak, Esra Ermis; Okay, Mufide; Kuku, Irfan; Hindilerden, Ipek Yonal; Topcuoglu, Pervin; Altuntas, Feviz; Karadogan, Ihsan; Pehlivan, Mustafa; Unal, Ali; Goker, Hakan; Erkurt, Mehmet Ali; Besisik, Sevgi Kalayoglu; Vural, Filiz
  • Küçük Resim Yok
    Öğe
    An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
    (Cig Media Group, Lp, 2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke
    [No Abstract Available]
  • Küçük Resim Yok
    Öğe
    An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy
    (Amer Soc Hematology, 2021) Sevindik, Omur Gokmen; Ozkurt, Zubeyde Nur; Boga, Can; Besisik, Sevgi Kalayoglu; Ipek, Yildiz; Geduk, Ayfer; Harmandali, Aybuke
    [No Abstract Available]
  • Küçük Resim Yok
    Öğe
    The Turkish experience with therapeutic plasma exchange: A national survey
    (Pergamon-Elsevier Science Ltd, 2019) Korkmaz, Serdal; Medeni, Serife Solmaz; Demirkan, Fatih; Besisik, Sevgi Kalayoglu; Dadin, Senem Altay; Cagliyan, Gulsum Akgun; Hacioglu, Sibel Kabukcu; Sari, Ismail; Sahin, Deniz Goren; Arat, Mutlu; Dagdas, Simten; Ozet, Gulsum; Kutlu, Nermin; Akyol, Tulay Karaagac; Ozcebe, Osman Ilhami; Teke, Hava Uskudar; Unal, Demet Kiper; Guner, Naile; Tombak, Anil; Celik, Halil; Bay, Ilker; Kiki, Ilhami; Ozgur, Gokhan; Erkurt, Mehmet Ali; Ozatli, Duzgun; Meletli, Ozgur; Demircioglu, Sinan; Demir, Cengiz; Kurtoglu, Erdal; Vural, Filiz; Tobu, Mahmut; Karakus, Abdullah; Ayyildiz, Orhan; Dal, Mehmet Sinan; Ozturk, Berna Afacan; Albayrak, Murat; Ocakci, Serkan; Bolaman, Zahit; Sonmez, Mehmet; Karakus, Volkan; Sevindik, Omur Gokmen; Berber, Ilhami; Dogu, Mehmet Hilmi; Gulturk, Emine; Ulas, Turgay; Payzin, Bahriye; Kuku, Irfan; Cagirgan, Seckin; Altuntas, Fevzi
    Therapeutic plasma exchange (TPE) is used to treat more than 60 diseases worldwide and has drawn growing interest. Little is known about the current situation of TPE activity in Turkey, so we developed a survey to obtain information about this timely topic. We collected data on TPE from 28 apheresis units throughout Turkey. We performed a total of 24,912 TPE procedures with 3203 patients over the past decade. Twenty years ago, the majority of procedures were performed for neurological and hematological disorders, and today, most TPE procedures are done for the same reasons. The only historical change has been an increase in TPE procedures in renal conditions. Currently, renal conditions were more frequently an indication for TPE than rheumatic conditions. Fresh frozen plasma was the most frequently used replacement fluid, followed by 5% albumin, used in 57.9% and 34.6% of procedures, respectively. The most frequently used anticoagulants in TPE were ACD-A and heparin/ACD-A, used with 1671 (52.2%) and 1164 (36.4%) patients, respectively. The frequency of adverse events (AEs) was 12.6%. The most common AEs were hypocalcemia-related symptoms, hypotension, and urticaria. We encountered no severe AEs that led to severe morbidity and mortality. Overall, more than two thirds of the patients showed improvement in the underlying disease. Here, we report on a nationwide survey on TPE activity in Turkey. We conclude that there has been a great increase in apheresis science, and the number of TPE procedures conducted in Turkey has increased steadily over time. Finally, we would like to point out that our past experiences and published international guidelines were the most important tools in gaining expertise regarding TPE.